J&J, Bayer can celebrate with ACS data on Xarelto

The big American Heart Association confab has begun, and already it has produced some big news. Data on Bayer and Johnson & Johnson's ($JNJ) Xarelto has doctors predicting a new standard of care in a new use that could spell billions in sales for the new-generation anti-clotting drug. The data, recently announced in brief, gives Xarelto a boost against other new drugs in that class, including Boehringer Ingelheim's Pradaxa and Pfizer ($PFE) and Bristol-Myers Squibb's ($BMY) forthcoming Eliquis.

Patients recovering from heart attack or severe chest pain--aka, those with acute coronary syndrome, or ACS--are much less likely to die or have another heart attack or stroke if they add a very low dose of Xarelto to standard anti-clotting therapy, a 15,000-plus patient study found. Death risk for the Xarelto patients was 34% lower than in patients on the usual treatment. It's "a new standard of anti-thrombotic therapy," one AHA commentator said (as quoted by Reuters).

This could mean big money for J&J and Bayer: The ACS market may be worth $3 billion, Reuters said, while Bloomberg puts the market at $1 billion-plus. The companies plan to ask the FDA for the indication by year's end; Xarelto is already approved for stroke prevention in patients with atrial fibrillation, as well as for clot prevention after certain surgeries.

"You only have to treat 56 patients to save a life. It's hard not to be excited by the mortality benefit," said Dr. Michael Gibson, the study's lead investigator (as quoted by Reuters), adding, "[i]f it is approved (for this use) I think it will be widely adopted."

- read the story from Reuters
- get more from Bloomberg

Suggested Articles

Esperion's Nexletol has had a rough road to approval after safety concerns nearly derailed its quest. But an FDA nod has the drug ready for market.

In an interview with Israel's Calcalist, Teva CEO Kåre Schultz shared details of his approach to the company's turnaround.

Nerlynx is already struggling in its extended adjuvant breast cancer setting, and new entrants from Daiichi-AZ and SeaGen could pressure it elsewhere.